


APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 2




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

WO 98/23299


PCT/CA97/00892

3/9


Oligonucleotide synthesized in 2 parts




Label 5' end of one sequence



Anneal both parts to complementary sequence



Ligate the 2 parts of the oligonucleotide



Separate the 2 strands and purify the oligonucleotide




Fig. 3


APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

0243460

^{32}P labelled oligonucleotide stability

Incubation period with SMC (d)

0 1 2 3 4 5 6 7



APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Revised





Fig. 5

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



Irradiation period (d) Fig. 6

FOUO 0211203




Fig. 7

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

0077E479.000001




Fig. 8

APPROVED	O. G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

00725479-02004




Fig. 1

Figure 1: Effect of 32P internally labeled oligonucleotides on smooth muscle cells proliferation




Fig. 10

APPROVED	O.G. FIG.	
BY	GLASS	SUBCLASS
DRAFTSMAN	•	

FIG. 12A



Fig. 12A




Fig. 12B




Fig. 12C

